≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Congenital vesicoureteral reflux

Endpoint Browser PheWeb

Q17_CONGENITAL_VESICOURETERAL_REFLUX

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q62.7
  • Cause of death: ICD-10 — Q62.7

2 out of 7 registries used, show all original rules.

245

4. Check minimum number of events

None

245

5. Include endpoints

None

245

6. Filter based on genotype QC (FinnGen only)

235

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Similar endpoints

↥

List of similar endpoints to Congenital vesicoureteral reflux based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Similar with more cases:

Venn diagram with a set fully inside an highlighted set Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 235 171 64
Unadjusted period prevalence (%) 0.05 0.06 0.03
Median age at first event (years) 4.62 5.38 2.58

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
245
Matched controls
2450
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q62.7
ICD-10 Finland
Congenital vesico-uretero-renal reflux
+∞
307.7
245
*
UKC02
NOMESCO Finland
Cystoscopy
48.3
169.8
109
40
G04AC01, ,
ATC
76.5
148.1
82
16
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
19.5
126.0
135
145
J01EA01
ATC
trimethoprim; systemic
14.7
101.8
169
322
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
24.5
97.9
77
45
KBV52
NOMESCO Finland
Cystoscopic injection therapy for vesicourethral reflux
+∞
96.4
86
*
N13.7
ICD-10 Finland
Vesicoureteral-reflux-associated uropathy
128.9
56.7
59
6
J01XE01
ATC
nitrofurantoin; oral
134.5
51.1
53
5
5937A
ICD-9 Finland
Other disorders of kidney and ureter, Vesicoureteric reflux
289.2
47.8
47
*
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
14.3
46.8
46
39
XKD00
NOMESCO Finland
Uroflowmetry
13.3
46.5
48
44
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
6.0
38.5
92
223
1530
FHL
Urethrocystoscopy
81.5
37.3
41
6
204
Kela drug reimbursment
Leukemia lymphatica
57.6
37.1
43
9
5901A
ICD-9 Finland
Infections of kidney, Acute pyelonephritis
135.4
33.6
35
*
KBH20
NOMESCO Finland
Replantation of ureter
78.5
30.8
34
5
TKC20
NOMESCO Finland
Catheterisation of bladder
10.5
24.9
29
31
G04BD04
ATC
oxybutynin; oral, transdermal
10.4
24.0
28
30
XKC03
NOMESCO Finland
Water cystometry
40.8
23.6
29
8
J01DA01
ATC
[U] cefalexin
3.7
21.4
164
864
KC1JB
NOMESCO Finland
Miktiocystography with X-ray
66.1
21.3
24
*
Q62.0
ICD-10 Finland
Congenital hydronephrosis
76.1
19.0
21
*
KH1EE
NOMESCO Finland
Urologic ultrasound examination
57.1
18.3
21
*
J01MA02
ATC
ciprofloxacin; systemic
3.4
17.3
83
319
N18.8
ICD-10 Finland
Other chronic renal failure
28.0
17.3
23
9
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
14.9
17.0
28
21
Q64.2
ICD-10 Finland
Congenital posterior urethral valves
+∞
16.9
16
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
16.6
64
213
N30.0
ICD-10 Finland
Acute cystitis
3.2
15.4
82
333
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
22.8
14.9
21
10
R50.9
ICD-10 Finland
Fever, unspecified
3.2
14.8
77
307
KA1AE
NOMESCO Finland
Kidney ultrasound examination
17.5
13.7
21
13
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
19.6
13.6
20
11
ZXD10
NOMESCO Finland
Scheduled procedure
2.8
12.9
99
483
Z94.0
ICD-10 Finland
Kidney transplant status
13.5
11.9
20
16
7187
FHL
Ureterohydroplasty due to reflux, for example
+∞
11.5
11
*
KAS20
NOMESCO Finland
Allogenic transplantation of kidney from living donor
36.9
11.4
14
*
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
12.0
11.3
20
18
N18.0
ICD-10 Finland
End-stage renal disease
45.5
11.0
13
*
7219
FHL
Other measure in this category
62.8
10.7
12
*
Q62.5
ICD-10 Finland
Duplication of ureter
114.7
10.5
11
*
A11CC03
ATC
alfacalcidol; systemic
10.3
10.5
20
21
5990C
ICD-9 Finland
Other disorders of urethra and urinary tract, Urinary tract infection, site not specified[INFECTIO VIARUM URINARIUM RECIDIVANS]
57.3
9.7
11
*
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
18.4
9.5
14
8
5910A
ICD-9 Finland
Hydronephrosis[HYDRONEPHROSIS]
+∞
9.4
9
*
KCW98
NOMESCO Finland
Other transluminal endoscopic operation on bladder
+∞
9.4
9
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
12.1
9.2
16
14
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
16.4
9.1
14
9
127
Kela drug reimbursment
Transplant complication
8.5
9.0
19
24
B34.9
ICD-10 Finland
Viral infection, unspecified
3.8
9.0
29
84
L04AD02
ATC
tacrolimus; systemic
11.3
8.9
16
15
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
2.2
8.8
134
857
TKC22
NOMESCO Finland
Catheterisation instruction
51.9
8.7
10
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.1
8.5
24
63
UKB02
NOMESCO Finland
Retrograde ureteroscopy
93.1
8.5
9
*
KDD52
NOMESCO Finland
Urethroscopic excision of urethral valve
+∞
8.4
8
*
KDV20
NOMESCO Finland
Submucous urethral injection
+∞
8.4
8
*
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
4.2
8.1
22
56
A12AA04
ATC
calcium carbonate; oral
11.3
7.9
14
13
WX408
NOMESCO Finland
General anesthesy, balanced
2.3
7.8
72
370
KA1FN
NOMESCO Finland
Isotope renography
25.9
7.6
10
*
R31
ICD-10 Finland
Unspecified haematuria
6.3
7.5
19
32
ZXE00
NOMESCO Finland
One hour or less
2.1
7.4
104
632
Q62.2
ICD-10 Finland
Congenital megaloureter
+∞
7.3
7
*
N13.9
ICD-10 Finland
Obstructive and reflux uropathy, unspecified
+∞
7.3
7
*
C09AA02
ATC
enalapril; systemic
4.7
7.3
17
38
U14
ICPC
Kidney symptom/complaint
20.8
7.2
10
5
ZX120
NOMESCO Finland
Intravenous
3.4
7.1
26
82
C08CA01
ATC
amlodipine; oral
3.3
6.8
26
84
KAC00
NOMESCO Finland
Nephrectomy
41.2
6.8
8
*
5990B
ICD-9 Finland
Other disorders of urethra and urinary tract, Urinary tract infection, site not specified[INFECTIO VIARUM URINARIUM ACUTA]
23.3
6.7
9
*
L04AA06
ATC
mycophenolic acid; systemic
8.2
6.7
14
18
J01DA09
ATC
[U] cefadroxil
2.3
6.7
62
318
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.0
6.7
31
113
N30.9
ICD-10 Finland
Cystitis, unspecified
3.1
6.6
29
102
RD210, ,
NOMESCO Finland
3.7
6.6
21
60
R4190
NOMESCO Finland
Nutritional therapy
3.0
6.6
31
114
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
3.8
6.5
20
56
Z3226
NOMESCO Finland
Physiotherapist
2.3
6.4
55
272
H02AB04
ATC
methylprednisolone; systemic
3.3
6.4
25
82
ZXD20
NOMESCO Finland
Day surgery
2.8
6.4
34
134
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.4
6.3
50
239
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
18.6
6.3
9
5
R4110
NOMESCO Finland
Physiotherapy
2.2
6.3
62
325
TKD00
NOMESCO Finland
Dilatation of urethra
+∞
6.3
6
*
Q62.8
ICD-10 Finland
Other congenital malformations of ureter
+∞
6.3
6
*
7186
FHL
Ureteroplasty, narrowing and resection (includes neoimplantation)
+∞
6.3
6
*
KBV00
NOMESCO Finland
Insertion of stent into ureter
27.4
6.3
8
*
XF600
NOMESCO Finland
Bloodpressure measurement
3.1
6.2
26
89
J01MA06
ATC
norfloxacin; oral
5.8
6.1
16
29

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
trimethoprim; oral, parenteral
J01EA01 [21602931]
3.7e+00
3.9e+00
1.0e+50
—
—
—
2.3e+00
cases:37.62%
controls:1.39%
cases:25.93%
controls:0.72%
cases:5.56%
controls:0.00%
—
—
—
—
—
—
cases:21.70%
controls:2.59%
38
13
63
922
28
7
80
971
6
0
102
978
—
—
—
23
25
83
941
Pediatric Surgery
OMOP4822020 [45756819]
1.4e+00
9.8e-01
—
1.0e+50
—
2.2e+00
2.3e+00
cases:10.89%
controls:2.99%
cases:5.56%
controls:2.15%
—
—
cases:13.89%
controls:0.00%
—
—
cases:16.67%
controls:2.25%
cases:40.57%
controls:6.63%
11
28
90
907
6
21
102
957
—
15
0
93
978
—
18
22
90
954
43
64
63
902
Outpatient Hospital
22 [8756]
7.9e-01
4.8e-01
—
—
2.4e+00
1.8e+00
6.9e-01
cases:32.67%
controls:18.07%
cases:11.11%
controls:7.16%
—
—
—
—
cases:11.11%
controls:1.12%
cases:25.93%
controls:5.53%
cases:27.36%
controls:15.84%
33
169
68
766
12
70
96
908
—
—
12
11
96
967
28
54
80
922
29
153
77
813
Pediatric Nephrology
OMOP4822026 [45756813]
—
2.4e+00
—
—
—
—
2.4e+00
—
—
cases:5.56%
controls:0.51%
—
—
—
—
—
—
—
—
cases:6.60%
controls:0.62%
—
6
5
102
973
—
—
—
—
7
6
99
960
Outpatient Visit
OP [9202]
7.1e-01
5.1e-01
-7.9e-01
—
1.0e+00
8.6e-01
1.2e+00
cases:55.45%
controls:37.97%
cases:50.00%
controls:37.42%
cases:5.56%
controls:11.45%
—
—
cases:28.70%
controls:12.37%
cases:61.11%
controls:39.86%
cases:84.91%
controls:62.01%
56
355
45
580
54
366
54
612
6
112
102
866
—
31
121
77
857
66
389
42
587
90
599
16
367
Inpatient Hospital
21 [8717]
4.5e-01
8.6e-01
—
1.0e+50
2.0e+00
9.7e-01
1.8e-02
cases:42.57%
controls:32.19%
cases:26.85%
controls:13.50%
—
—
cases:15.74%
controls:0.00%
cases:11.11%
controls:1.74%
cases:24.07%
controls:10.76%
cases:30.19%
controls:29.81%
43
301
58
634
29
132
79
846
—
17
0
91
978
12
17
96
961
26
105
82
871
32
288
74
678
Acute tubulo-interstitial nephritis
N10 [45543856]
—
—
—
—
—
—
3.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:16.04%
controls:0.72%
—
—
—
—
—
—
17
7
89
959
Emergency Room Visit
ER [9203]
7.9e-01
1.2e+00
—
—
1.9e+00
5.5e-01
4.0e-01
cases:27.72%
controls:14.87%
cases:25.00%
controls:9.30%
—
—
—
—
cases:6.48%
controls:1.02%
cases:14.81%
controls:9.12%
cases:35.85%
controls:27.23%
28
139
73
796
27
91
81
887
—
—
7
10
101
968
16
89
92
887
38
263
68
703
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
3.0e+00
—
—
—
—
—
1.3e+00
cases:12.87%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
cases:7.55%
controls:2.07%
13
7
88
928
—
—
—
—
—
8
20
98
946
cefalexin; oral
J01DB01 [21602870]
1.2e+00
1.6e+00
—
—
—
8.0e-01
6.1e-01
cases:43.56%
controls:19.14%
cases:27.78%
controls:7.16%
—
—
—
—
—
—
cases:14.81%
controls:7.27%
cases:37.74%
controls:24.84%
44
179
57
756
30
70
78
908
—
—
—
16
71
92
905
40
240
66
726
Urology
34 [38004474]
—
—
—
1.0e+50
—
—
2.8e+00
—
—
—
—
—
—
cases:7.41%
controls:0.00%
—
—
—
—
cases:10.38%
controls:0.72%
—
—
—
8
0
100
978
—
—
11
7
95
959
nitrofurantoin; oral
J01XE01 [21603058]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:14.15%
controls:1.04%
—
—
—
—
—
—
15
10
91
956
General Surgery
2 [38004447]
4.9e-01
—
—
1.0e+50
—
1.6e+00
8.8e-01
cases:10.89%
controls:6.95%
—
—
—
—
cases:11.11%
controls:0.00%
—
—
cases:12.96%
controls:2.87%
cases:21.70%
controls:10.35%
11
65
90
870
—
—
12
0
96
978
—
14
28
94
948
23
100
83
866
sulfadiazine and trimethoprim
J01EE02 [21602962]
9.5e-01
1.5e+00
-1.0e+50
—
—
6.5e-01
9.5e-01
cases:33.66%
controls:16.36%
cases:13.89%
controls:3.37%
cases:0.00%
controls:1.02%
—
—
—
—
cases:6.48%
controls:3.48%
cases:15.09%
controls:6.42%
34
153
67
782
15
33
93
945
0
10
108
968
—
—
7
34
101
942
16
62
90
904
Scheduled procedure
ZXD10 [2001311387]
—
9.7e-01
—
1.0e+50
—
1.9e+00
1.3e+00
—
—
cases:6.48%
controls:2.56%
—
—
cases:9.26%
controls:0.00%
—
—
cases:12.04%
controls:1.95%
cases:10.38%
controls:3.00%
—
7
25
101
953
—
10
0
98
978
—
13
19
95
957
11
29
95
937
Pediatric Medicine
37 [38004477]
7.4e-01
8.2e-01
-5.8e-01
—
5.4e-01
3.8e-01
4.4e-01
cases:54.46%
controls:36.36%
cases:47.22%
controls:28.32%
cases:5.56%
controls:9.51%
—
—
cases:13.89%
controls:8.59%
cases:37.04%
controls:28.59%
cases:48.11%
controls:37.47%
55
340
46
595
51
277
57
701
6
93
102
885
—
15
84
93
894
40
279
68
697
51
362
55
604
One hour or less
ZXE00 [2001311394]
5.6e-01
5.9e-01
—
1.0e+50
—
1.5e+00
9.1e-01
cases:4.95%
controls:2.89%
cases:5.56%
controls:3.17%
—
—
cases:9.26%
controls:0.00%
—
—
cases:11.11%
controls:2.66%
cases:9.43%
controls:4.04%
5
27
96
908
6
31
102
947
—
10
0
98
978
—
12
26
96
950
10
39
96
927
pivmecillinam; oral
J01CA08 [21602827]
1.2e+00
—
—
—
—
—
1.2e+00
cases:6.93%
controls:2.14%
—
—
—
—
—
—
—
—
—
—
cases:12.26%
controls:3.93%
7
20
94
915
—
—
—
—
—
13
38
93
928
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
5.6e-01
—
—
—
—
—
—
cases:4.95%
controls:2.89%
—
—
—
—
—
—
—
—
—
—
—
—
5
27
96
908
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
8
108
970
—
—
—
—
—
fluticasone, combinations
R01AD58 [43534837]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
106
958
prednisone
A07EA03 [21600655]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
108
971
—
ibuprofen
R02AX02 [1588667]
-3.1e-01
—
—
—
—
—
-1.1e-01
cases:4.95%
controls:6.63%
—
—
—
—
—
—
—
—
—
—
cases:8.49%
controls:9.42%
5
62
96
873
—
—
—
—
—
9
91
97
875
Physiotherapist
Z3226 [2001311560]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
0
10
108
968
—
—
—
—
—
pimecrolimus
D11AH02 [21602339]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
5.6e-01
—
—
—
—
—
—
cases:4.95%
controls:2.89%
—
—
—
—
—
—
—
—
—
—
—
—
5
27
96
908
—
—
—
—
—
—
Nausea and vomiting
R11 [45539317]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
0
6
101
929
—
—
—
—
—
0
7
106
959
hydroxychloroquine; oral
P01BA02 [21604889]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:0.62%
0
5
101
930
0
5
108
973
—
—
—
0
5
108
971
0
6
106
960
tizanidine; oral
M03BX02 [21604116]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
8
108
970
—
—
—
—
—
prednisolone
S01BA04 [21603621]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Outcome of delivery
Z37 [45581024]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.25%
cases:0.00%
controls:0.61%
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
21
101
914
0
6
108
972
—
—
—
0
7
108
969
—
terfenadine; oral
R06AX12 [21603513]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
101
922
—
—
—
—
—
—
Administration of medicine
SPAT1254 [2001700355]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Medical examin/health eval partial
-31 [2002000102]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
9
106
957
Place of Employment-Worksite
18 [581475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Pain in joint
M25.5 [45586941]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
101
929
—
—
—
—
—
—
Pediatric Gastroenterology
OMOP4822029 [45756810]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
glucagon; nasal, parenteral
H04AA01 [21602778]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:4.50%
cases:0.00%
controls:0.82%
—
—
cases:0.00%
controls:0.72%
cases:0.00%
controls:5.02%
—
—
—
0
44
108
934
0
8
108
970
—
0
7
108
971
0
49
108
927
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
—
—
-1.0e+50
—
—
1.6e+00
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
cases:5.56%
controls:1.23%
—
—
—
—
0
7
108
971
—
—
6
12
102
964
—
salbutamol; oral, parenteral
R03CC02 [21603312]
6.1e-01
—
—
—
—
—
—
cases:15.84%
controls:9.30%
—
—
—
—
—
—
—
—
—
—
—
—
16
87
85
848
—
—
—
—
—
—
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
0
6
108
970
—
Diabetes mellitus arising in pregnancy
O24.4 [45543922]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
9
106
957
astemizole; oral
R06AX11 [21603512]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
101
928
—
—
—
—
—
—
Personal history of leukaemia
Z85.6 [45609980]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
9
106
957
clindamycin; vaginal
G01AA10 [21602372]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
—
dexamethasone
S03BA01 [21605201]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
9
106
957
CBC panel - Blood by Automated count
58410-2 [40761511]
—
—
—
—
—
6.5e-01
6.1e-02
—
—
—
—
—
—
—
—
—
—
cases:4.63%
controls:2.46%
cases:4.72%
controls:4.45%
—
—
—
—
—
5
24
103
952
5
43
101
923
combinations of corticosteroids
D07AB30 [21602118]
-1.5e-01
—
—
—
—
—
-2.0e-01
cases:7.92%
controls:9.09%
—
—
—
—
—
—
—
—
—
—
cases:5.66%
controls:6.83%
8
85
93
850
—
—
—
—
—
6
66
100
900
Implantation of epicardial pacemaker with ventricular electrode
FPF00 [2001303181]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
triamcinolone; nasal
R01AD11 [21605052]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
0
13
106
953
triamcinolone and antiseptics
D07BB03 [21602150]
2.2e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.94%
controls:4.81%
cases:0.00%
controls:1.43%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
6
45
95
890
0
14
108
964
—
—
—
0
11
108
965
—
Lumbar puncture
TAB00 [2001300538]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
0
11
108
967
—
—
—
0
6
108
970
—
pivampicillin; oral
J01CA02 [21602821]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
101
918
—
—
—
—
—
—
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
—
—
—
—
—
—
4.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.66%
controls:3.62%
—
—
—
—
—
—
6
35
100
931
Chronic tonsillitis
J35.0 [45548113]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
metoprolol; oral, parenteral
C07AB02 [21601684]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Other minor procedure in endocrine surgery
TBW99 [2001300856]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
hydroxyzine; oral, parenteral
N05BB01 [21604590]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
insulin aspart; parenteral
A10AD05 [21600733]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
0
6
108
972
—
—
lidocaine
R02AD02 [21603243]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
101
927
—
—
—
—
—
—
Other measure in this category
9759 [2000101678]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
Headache
N01 [2002000720]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
106
958
dexamethasone
D07AB19 [21602116]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay
46083-2 [3043362]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
—
hydrocortisone
S02BA01 [21605166]
2.1e-01
8.5e-01
-1.0e+50
—
—
-1.0e+50
-8.4e-02
cases:11.88%
controls:9.84%
cases:5.56%
controls:2.45%
cases:0.00%
controls:0.51%
—
—
—
—
cases:0.00%
controls:2.15%
cases:6.60%
controls:7.14%
12
92
89
843
6
24
102
954
0
5
108
973
—
—
0
21
108
955
7
69
99
897
Case Management Agency
251B00000X [38004193]
-6.6e-01
1.9e-02
—
—
—
-3.8e-01
-9.9e-02
cases:11.88%
controls:20.64%
cases:9.26%
controls:9.10%
—
—
—
—
—
—
cases:7.41%
controls:10.45%
cases:19.81%
controls:21.43%
12
193
89
742
10
89
98
889
—
—
—
8
102
100
874
21
207
85
759
betamethasone
A07EA04 [21600656]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
0
9
101
926
0
7
108
971
—
—
—
—
—
Cystoscopic injection therapy for vesicourethral reflux
KBV52 [2001305901]
—
—
—
1.0e+50
—
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:12.04%
controls:0.00%
—
—
cases:13.89%
controls:0.00%
cases:11.32%
controls:0.00%
—
—
—
13
0
95
978
—
15
0
93
976
12
0
94
966
pH of Capillary blood
2745-8 [3009343]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
8
108
970
—
—
—
—
—
Other investigative procedure of eye
XCW99 [2001301491]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
9
106
957
miconazole
D01AC02 [21601921]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
108
972
—
—
—
—
—
Disturbance of activity and attention
F90.0 [45542870]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Two-surface restoration
SFA20 [2001310359]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
0
8
108
970
—
—
—
0
6
108
970
—
cetirizine; oral
R06AE07 [21603497]
-1.7e-02
—
—
—
-1.0e+50
—
-3.4e-01
cases:9.90%
controls:10.05%
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
cases:7.55%
controls:10.25%
10
94
91
841
—
—
—
0
8
108
970
—
8
99
98
867
epinephrine; parenteral
C01CA24 [21600303]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
108
971
—
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
101
929
—
—
—
—
—
—
Acute maxillary sinusitis
J01.0 [45601112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
101
929
—
—
—
—
—
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
-5.1e-02
—
—
—
—
—
-2.5e-01
cases:14.85%
controls:15.51%
—
—
—
—
—
—
—
—
—
—
cases:7.55%
controls:9.52%
15
145
86
790
—
—
—
—
—
8
92
98
874
Supervision of other normal pregnancy
Z34.8 [45537628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Audiology
64 [38004489]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.72%
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:1.13%
cases:0.00%
controls:2.28%
0
9
101
926
0
7
108
971
—
—
0
5
108
973
0
11
108
965
0
22
106
944
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
—
—
—
—
—
—
7.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:2.28%
—
—
—
—
—
—
5
22
101
944
Body mass index
60621009 [4245997]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:5.62%
—
—
—
—
—
—
—
—
—
—
—
0
55
108
923
—
—
—
—
—
Cathetrisation of vein
TPH04 [2001309597]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.66%
controls:0.93%
—
—
—
—
—
—
6
9
100
957
Cathetrisation of artery
TPH07 [2001309747]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
101
929
—
—
—
—
—
—
Children's severe malnutrition
602 [2001600367]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
0
5
101
930
0
5
108
973
—
—
—
0
5
108
971
—
Contusion of finger(s) without damage to nail
S60.0 [45535417]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
dexamethasone and antiinfectives
S02CA06 [21605178]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
101
928
—
—
—
—
—
—
Extensive health check-up of expecting family
SPAT1197 [2001700298]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
mometasone; nasal
R01AD09 [21605051]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.84%
—
—
—
—
—
—
cases:0.00%
controls:1.84%
—
—
—
0
18
108
960
—
—
—
0
18
108
958
—
Diseases of nail, Ingrowing nail
7030A [2000405587]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
calcium (different salts in combination); oral
A12AA20 [21600872]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:1.02%
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
0
11
101
924
0
10
108
968
—
—
—
0
10
108
966
—
Pregnancy confirmed
Z32.1 [45566418]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
106
958
saccharomyces boulardii; oral
A07FA02 [21600670]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Extensive health check-up on first grade
SPAT1384 [2001700484]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
0
8
108
968
—
Nonsuppurative otitis media, unspecified
H65.9 [45605737]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
101
927
—
—
—
—
—
—
Wheezing
R06.2 [45548946]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
6
101
929
0
5
108
973
—
—
—
—
—
Abdominal ultrasound examination
JN3AE [2001305555]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
8
108
970
—
—
—
—
—
hydrocortisone butyrate
D07AB02 [21602106]
1.8e-01
8.1e-01
-1.0e+50
—
—
-1.0e+50
1.4e-02
cases:11.88%
controls:10.16%
cases:5.56%
controls:2.56%
cases:0.00%
controls:0.51%
—
—
—
—
cases:0.00%
controls:2.25%
cases:7.55%
controls:7.45%
12
95
89
840
6
25
102
953
0
5
108
973
—
—
0
22
108
954
8
72
98
894
Oncology Clinic/Center
261QX0200X [38004268]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:1.23%
—
—
—
—
—
—
—
—
—
—
0
9
101
926
0
12
108
966
—
—
—
—
—
Dental examination
Z01.2 [45581002]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
4.7e-01
cases:0.00%
controls:0.86%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
cases:0.00%
controls:1.23%
cases:6.60%
controls:4.24%
0
8
101
927
0
9
108
969
—
—
—
0
12
108
964
7
41
99
925
hydrocortisone
D07XA01 [21602180]
2.2e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.94%
controls:4.81%
cases:0.00%
controls:1.43%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
6
45
95
890
0
14
108
964
—
—
—
0
11
108
965
—
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83 [45552036]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Insulin-dependent diabetes diabetic hypoglycemic coma
E10.00 [2000501424]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.25%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
0
21
101
914
0
7
108
971
—
—
—
0
5
108
971
—
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
11
108
967
—
0
6
108
972
—
—
Delivery by emergency caesarean section
O82.10 [2000503217]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
Hypermetropia
H52.0 [45543078]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
9
106
957
Approximal wear
K03.00 [2000502665]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Pediatric Infectious Diseases
OMOP4822027 [45756812]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.61%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
0
6
101
929
0
6
108
972
—
—
—
0
5
108
971
—
amoxicillin; oral, parenteral
J01CA04 [21602823]
-9.2e-02
3.1e-01
—
—
—
-3.5e-01
1.7e-01
cases:48.51%
controls:50.80%
cases:21.30%
controls:16.56%
—
—
—
—
—
—
cases:10.19%
controls:13.83%
cases:34.91%
controls:31.06%
49
475
52
460
23
162
85
816
—
—
—
11
135
97
841
37
300
69
666
Restricted health certificate
SPAT1283 [2001700384]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
0
8
101
927
—
—
—
—
—
0
9
106
957
Coeliac disease
K90.0 [45586745]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
—
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
8
108
970
—
—
—
—
—
opium derivatives and expectorants
R05FA02 [21603439]
2.1e-01
—
—
—
—
-1.0e+50
—
cases:6.93%
controls:5.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
7
53
94
882
—
—
—
—
0
13
108
963
—
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
—
—
—
—
—
—
-2.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:5.69%
—
—
—
—
—
—
5
55
101
911
amlodipine; oral
C08CA01 [21601747]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
—
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
6
101
929
0
5
108
973
—
—
—
0
7
108
969
—
piroxicam; ointment
M02AA07 [21604043]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
0
14
106
952
Pediatric Cardiology
OMOP4821938 [45756805]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
101
927
—
—
—
—
—
—
insulin (beef); parenteral
A10AD02 [21600730]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
doxylamine, combinations
R06AA59 [40254475]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
0
10
108
966
—
Extensive health check-up at 4 months of age
SPAT1381 [2001700481]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
101
927
—
—
—
—
—
—
Planned health check-up monitoring, health check-up performed based on individual need
SPAT1317 [2001700418]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:1.45%
—
0
6
108
972
—
—
—
0
6
108
970
0
14
106
952
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
2.1e-01
—
—
—
—
-1.0e+50
—
cases:6.93%
controls:5.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
7
53
94
882
—
—
—
—
0
13
108
963
—
Pediatric Hematology-Oncology
OMOP4822028 [45756811]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.75%
cases:0.00%
controls:1.43%
cases:0.00%
controls:0.72%
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:1.13%
cases:0.00%
controls:1.04%
0
7
101
928
0
14
108
964
0
7
108
971
—
0
6
108
972
0
11
108
965
0
10
106
956
Lower uterine segment caesarean section
MCA10 [2001306959]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
9
106
957
Vesicoureteral-reflux-associated uropathy
N13.7 [45539031]
1.0e+50
1.0e+50
—
—
—
—
1.0e+50
cases:14.85%
controls:0.00%
cases:12.96%
controls:0.00%
—
—
—
—
—
—
—
—
cases:7.55%
controls:0.00%
15
0
86
935
14
0
94
978
—
—
—
—
8
0
98
966
Diabetes mellitus screening
171183004 [4064918]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.66%
0
5
101
930
—
—
—
—
—
0
16
106
950
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
0
11
108
967
—
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: Unspecified
SMOKING-1-1-0 [2002330116]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
101
929
—
—
—
—
—
—
clindamycin
D10AF01 [21602305]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
10
106
956
ECG with 12 standard connections
XF400 [2001303368]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:1.66%
—
—
—
—
—
0
6
108
970
0
16
106
950
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
0
7
108
971
—
—
—
—
—
Topical pimecrolimus and tacrolimus
317 [2001600278]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
Teeth/gum symptom/complaint
D19 [2002000318]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
5
101
930
—
—
—
—
—
0
6
106
960
Body height measure
50373000 [4177340]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:5.62%
—
—
—
—
—
—
—
—
—
—
—
0
55
108
923
—
—
—
—
—
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
—
9.5e-01
-1.0e+50
—
—
—
—
—
—
cases:4.63%
controls:1.84%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
5
18
103
960
0
5
108
973
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
7
101
928
0
5
108
973
—
—
—
—
—
cough suppressants and expectorants
R05FB02 [21603442]
2.8e-01
—
—
—
—
-1.0e+50
—
cases:6.93%
controls:5.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
7
50
94
885
—
—
—
—
0
13
108
963
—
Detailed ultrasound examination of fetus including color doppler method
MA2DE [2001306835]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Paracentesis of tympanic membrane
DCA10 [2001301562]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
101
929
—
—
—
—
—
—
azathioprine; oral, parenteral
L04AX01 [21603927]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.72%
—
—
—
—
—
0
6
108
970
0
7
106
959
Supervision of normal first pregnancy
Z34.0 [45595500]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
0
11
106
955
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
0
6
108
970
—
Other measure in this category
7219 [2000101155]
1.0e+50
—
—
—
—
—
—
cases:4.95%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
—
5
0
96
935
—
—
—
—
—
—
Cervicocranial syndrome
M53.0 [45562750]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
insulin lispro; parenteral
A10AB04 [21600718]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.53%
—
—
cases:0.00%
controls:1.94%
—
—
—
—
—
—
0
15
108
963
—
0
19
108
959
—
—
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
—
—
—
—
—
—
7.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.72%
controls:2.28%
—
—
—
—
—
—
5
22
101
944
imiquimod
D06BB10 [21602092]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.24%
—
—
—
—
—
—
0
12
106
954
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
F70.0 [45595920]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Epilepsy, unspecified
G40.9 [45562083]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Other disorders of kidney and ureter, Vesicoureteric reflux
5937A [2000404665]
1.0e+50
—
—
—
—
—
—
cases:9.90%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
—
10
0
91
935
—
—
—
—
—
—
Type 1 diabetes mellitus, With renal complications
E10.2 [45586137]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
Treatment-related counselling outside office
SPAT1249 [2001700350]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
—
Monitoring of normal pregnancy
SPAT1196 [2001700297]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
combinations of penicillins
J01CR50 [21602867]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.23%
—
—
—
—
—
—
—
0
12
108
964
—
Headache
R51.80 [2000503603]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
0
5
108
973
—
—
—
0
6
108
970
—
combinations of corticosteroids
D07XB30 [21602188]
-1.5e-01
—
—
—
—
—
-2.0e-01
cases:7.92%
controls:9.09%
—
—
—
—
—
—
—
—
—
—
cases:5.66%
controls:6.83%
8
85
93
850
—
—
—
—
—
6
66
100
900
enoxaparin; parenteral
B01AB05 [21600976]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
levocetirizine; oral
R06AE09 [21603498]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
101
926
—
—
—
—
—
—
Rheumatology
66 [38004491]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
108
972
—
—
—
—
—
antibiotics in combination with other drugs
S01AA20 [21603571]
2.4e-01
-1.0e+50
—
—
—
—
-1.0e+50
cases:7.92%
controls:6.31%
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.83%
8
59
93
876
0
16
108
962
—
—
—
—
0
37
106
929
Vaccination
SPAT1325 [2001700426]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
0
15
106
951
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Office Visit
OMOP4822458 [581477]
-3.6e-02
-3.2e-02
—
—
—
-5.2e-01
-5.6e-01
cases:6.93%
controls:7.17%
cases:5.56%
controls:5.73%
—
—
—
—
—
—
cases:4.63%
controls:7.58%
cases:11.32%
controls:18.32%
7
67
94
868
6
56
102
922
—
—
—
5
74
103
902
12
177
94
789
Bacterial pneumonia, unspecified
J15.9 [45557621]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
0
7
101
928
—
—
—
—
—
0
11
106
955
Preventive oral health care, short
SCA01 [2001310302]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
101
924
—
—
—
—
—
—
Cystoscopy
UKC02 [2001306005]
1.0e+50
—
—
1.0e+50
1.0e+50
1.0e+50
—
cases:4.95%
controls:0.00%
—
—
—
—
cases:11.11%
controls:0.00%
cases:4.63%
controls:0.00%
cases:10.19%
controls:0.00%
—
—
5
0
96
935
—
—
12
0
96
978
5
0
103
978
11
0
97
976
—
Gas panel - Capillary blood
24337-8 [3022313]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
9
108
969
—
—
—
—
—
Asthma, Extrinsic asthma[EXTRINSIC ASTHMA SINE EXACERBATIONE]
4930A [2000403991]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
101
929
—
—
—
—
—
—
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
117 [2001600117]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
0
7
101
928
0
6
108
972
—
—
—
—
—
Tonsillectomy
EMB10 [2001302265]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
terbinafine; ointment
D01AE15 [21601954]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
Health check-up performed during first study year in students of upper secondary schools, vocational schools etc.
SPAT1363 [2001700464]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
azelaic acid; ointment
D10AX03 [21602314]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
0
11
106
955
fusidic acid; ointment
D06AX01 [21602062]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
0
11
108
967
—
—
—
0
5
108
971
—
metronidazole and furazolidone
P01AB51 [45893518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
Precursor cell lymphoblastic leukemia, NOS, of bone marrow
9835/3-C42.1 [44503066]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
0
6
101
929
0
6
108
972
—
—
—
—
—
Pediatric Endocrinology
OMOP4822030 [45756809]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
0
9
101
926
—
—
—
—
0
11
108
965
—
Removal of fixed intravenous catheter
TPH90 [2001309607]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
0
6
101
929
—
—
—
—
0
6
108
970
—
Pneumonia, unspecified
J18.9 [45601123]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
0
5
101
930
—
—
—
—
—
0
14
106
952
Endocrinology
46 [38004485]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:3.00%
0
6
101
929
0
7
108
971
—
—
—
0
5
108
971
0
29
106
937
Upper respiratory infection acute
R74 [2002000942]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
0
9
108
969
—
—
—
—
—
clindamycin; oral, parenteral
J01FF01 [21602985]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
101
925
—
—
—
—
—
—
tolfenamic acid; oral, rectal
M01AG02 [21603988]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
101
925
—
—
—
—
—
—
Mild depressive episode without somatic syndrome
F32.00 [2000501978]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Routine postpartum follow-up
Z39.2 [45547306]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
levocabastine
S01GX02 [21605086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
9
106
957
Hypersensitivity skin testing
268377001 [4147813]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:1.04%
0
8
101
927
—
—
—
—
0
5
108
971
0
10
106
956
natamycin; local oral
A01AB10 [21600020]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
101
924
—
—
—
—
—
—
Inpatient Visit
IP [9201]
8.7e-01
—
—
—
—
—
—
cases:9.90%
controls:4.39%
—
—
—
—
—
—
—
—
—
—
—
—
10
41
91
894
—
—
—
—
—
—
chlorhexidine
S03AA04 [21605193]
2.2e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.94%
controls:4.81%
cases:0.00%
controls:1.43%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
6
45
95
890
0
14
108
964
—
—
—
0
11
108
965
—
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
3.2e-01
2.7e-01
—
—
1.3e+00
4.6e-01
-2.4e-01
cases:4.95%
controls:3.64%
cases:5.56%
controls:4.29%
—
—
—
—
cases:4.63%
controls:1.33%
cases:5.56%
controls:3.59%
cases:4.72%
controls:5.90%
5
34
96
901
6
42
102
936
—
—
5
13
103
965
6
35
102
941
5
57
101
909
tranexamic acid; oral, parenteral
B02AA02 [21601036]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Intraoral radiographic dental examination
EB1AA [2001301903]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
108
972
—
—
—
—
—
telithromycin; oral
J01FA15 [21602983]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
flumetasone and antiinfectives
S02CA02 [21605174]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
101
924
—
—
—
—
—
—
COVID-19, virus not identified
U07.2 [45756094]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Impetigo [any organism] [any site]
L01.0 [45572243]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.2e-01
2.7e-01
—
—
1.3e+00
4.6e-01
-2.4e-01
cases:4.95%
controls:3.64%
cases:5.56%
controls:4.29%
—
—
—
—
cases:4.63%
controls:1.33%
cases:5.56%
controls:3.59%
cases:4.72%
controls:5.90%
5
34
96
901
6
42
102
936
—
—
5
13
103
965
6
35
102
941
5
57
101
909
propranolol; oral, parenteral
C07AA05 [21601670]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
108
972
—
—
—
—
—
Gastroenterology
10 [38004455]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
cefuroxime
S01AA27 [43534854]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
—
Differential panel, method unspecified - Blood
69738-3 [42870588]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
Ganglion
M67.4 [45582222]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
106
958
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
108
971
—
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Hand Surgery
40 [38004480]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
Simple examination of mouth
SAA01 [2001310274]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
0
7
108
971
—
—
—
0
6
108
970
—
Insertion of ventilating tube through tympanic membrane
DCA20 [2001301563]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
—
Diabetes insulin dependent
T89 [2002001130]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Unspecified acute lower respiratory infection
J22 [45586665]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Other and unspecified convulsions
R56.8 [45602033]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
Viral intestinal infection, unspecified
A08.4 [45576230]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:2.38%
—
—
—
—
—
0
8
108
968
0
23
106
943
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
0
13
106
953
azithromycin; oral, parenteral
J01FA10 [21602978]
-2.6e-01
-9.1e-02
—
—
—
-3.8e-01
-5.3e-02
cases:20.79%
controls:25.35%
cases:6.48%
controls:7.06%
—
—
—
—
—
—
cases:4.63%
controls:6.66%
cases:16.04%
controls:16.77%
21
237
80
698
7
69
101
909
—
—
—
5
65
103
911
17
162
89
804
Mixed specific developmental disorders
F83 [45595922]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.53%
cases:0.00%
controls:1.02%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
cases:0.00%
controls:1.14%
0
5
101
930
0
10
108
968
—
—
—
0
11
108
965
0
11
106
955
aciclovir
S01AD03 [21603588]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
betamethasone
C05AA05 [21601610]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
0
9
101
926
0
7
108
971
—
—
—
—
—
chlorhexidine, combinations
D08AC52 [21602208]
2.2e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.94%
controls:4.81%
cases:0.00%
controls:1.43%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
6
45
95
890
0
14
108
964
—
—
—
0
11
108
965
—
rota virus, pentavalent, live, reassorted
J07BH02 [21601357]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
101
928
—
—
—
—
—
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
—
7.8e-01
—
—
—
7.0e-01
—
—
—
cases:6.48%
controls:3.07%
—
—
—
—
—
—
cases:4.63%
controls:2.36%
—
—
—
7
30
101
948
—
—
—
5
23
103
953
—
Pharmacy visit
OMOP4822462 [581458]
6.0e-01
7.9e-01
1.8e-01
—
2.6e-01
3.7e-01
1.9e-01
cases:93.07%
controls:88.02%
cases:79.63%
controls:64.01%
cases:23.15%
controls:20.14%
—
—
cases:25.93%
controls:21.27%
cases:71.30%
controls:63.22%
cases:87.74%
controls:85.51%
94
823
7
112
86
626
22
352
25
197
83
781
—
28
208
80
770
77
617
31
359
93
826
13
140
Posterior or lateral fusion of thoracic spine with fixation, more than 3 vertebraea
NAG53 [2001307118]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
clobetasol
D07AD01 [21602141]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
prednisone; oral
H02AB07 [21602735]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
108
971
—
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
5.2e-01
—
—
—
—
—
—
cases:4.95%
controls:2.99%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
96
907
—
—
—
—
—
—
Orthopedic Surgery
20 [38004465]
—
—
—
—
—
-1.0e+50
5.4e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
cases:4.72%
controls:2.80%
—
—
—
—
—
0
7
108
969
5
27
101
939
Urinary tract infection, site not specified
N39.0 [45548665]
1.0e+50
—
—
—
—
—
—
cases:8.91%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
—
9
0
92
935
—
—
—
—
—
—
hydroxyethylpromethazine, combinations
R06AD55 [21603490]
2.8e-01
—
—
—
—
-1.0e+50
—
cases:6.93%
controls:5.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
7
50
94
885
—
—
—
—
0
13
108
963
—
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:6.44%
—
—
—
—
—
—
—
—
0
63
108
915
—
—
nystatin
D01AA01 [21601911]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
Pain in limb
M79.6 [45587063]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
101
926
—
—
—
—
—
—
Congenital heart failure surgery
31 [2002100109]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
clarithromycin; oral, parenteral
J01FA09 [21602977]
—
-1.0e+50
—
—
—
—
2.5e-01
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
cases:5.66%
controls:4.45%
—
0
8
108
970
—
—
—
—
6
43
100
923
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
—
8.4e-01
-1.0e+50
—
—
—
—
—
—
cases:4.63%
controls:2.04%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
5
20
103
958
0
5
108
973
—
—
—
—
dexamethasone; local oral
A01AC02 [21600035]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
fluticasone furoate; nasal
R01AD12 [21605053]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
cases:0.00%
controls:2.25%
—
—
—
—
0
5
108
973
—
—
0
22
108
954
—
triamcinolone and antiinfectives
S02CA04 [21605176]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
prednisolone; oral, parenteral
H02AB06 [21602734]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
—
—
—
—
—
—
—
—
—
0
13
108
965
—
—
—
—
—
pregabalin; oral
N02BF02 [955152]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Congenital vesico-uretero-renal reflux
Q62.7 [45568071]
—
—
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:77.78%
controls:0.00%
cases:31.48%
controls:0.00%
cases:48.15%
controls:0.00%
cases:53.77%
controls:0.00%
—
—
—
84
0
24
978
34
0
74
978
52
0
56
976
57
0
49
966
salbutamol; inhalant
R03AC02 [21603256]
—
—
—
—
—
—
-2.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.60%
controls:8.49%
—
—
—
—
—
—
7
82
99
884
Physiotherapy
R4110 [2001310233]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
108
971
—
Atrioventricular block, complete
I44.2 [45576872]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:0.52%
—
0
5
108
973
—
—
—
0
5
108
971
0
5
106
961
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
0
5
108
973
—
—
—
0
5
108
971
—
Coloscopy
UJF32 [2001305029]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
101
927
—
—
—
—
—
—
chlorhexidine
D09AA12 [21602275]
2.2e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.94%
controls:4.81%
cases:0.00%
controls:1.43%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
6
45
95
890
0
14
108
964
—
—
—
0
11
108
965
—
hydrocortisone and antiinfectives
S03CA04 [21605208]
2.9e-01
-1.0e+50
—
—
—
—
-1.0e+50
cases:5.94%
controls:4.49%
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.86%
6
42
95
893
0
11
108
967
—
—
—
—
0
18
106
948
Hand and fingers X-ray examination
ND2AA [2001307607]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
hydrocortisone buteprate
D07AB11 [21602115]
1.8e-01
8.1e-01
-1.0e+50
—
—
-1.0e+50
1.4e-02
cases:11.88%
controls:10.16%
cases:5.56%
controls:2.56%
cases:0.00%
controls:0.51%
—
—
—
—
cases:0.00%
controls:2.25%
cases:7.55%
controls:7.45%
12
95
89
840
6
25
102
953
0
5
108
973
—
—
0
22
108
954
8
72
98
894
dexamethasone
S01BA01 [21603618]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
9
106
957
Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay
46082-4 [3046524]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
—
dexchlorpheniramine, combinations
R06AB52 [21603467]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
0
10
108
966
—
Basic examination of mouth
SAA02 [2001310275]
—
—
—
—
—
—
1.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.43%
controls:8.39%
—
—
—
—
—
—
10
81
96
885
Acute lymphoblastic leukaemia [ALL]
C91.0 [45537873]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.64%
cases:0.00%
controls:1.23%
cases:0.00%
controls:1.02%
—
—
cases:0.00%
controls:1.02%
cases:0.00%
controls:1.23%
cases:0.00%
controls:1.04%
0
6
101
929
0
12
108
966
0
10
108
968
—
0
10
108
968
0
12
108
964
0
10
106
956
No procedures
SPAT1301 [2001700402]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
fexofenadine; oral
R06AX26 [21603525]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Other disorders of pancreatic internal secretion, Hypoglycaemic coma[COMA HYPOGLYCAEMICUM]
2510B [2000402332]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
2.2e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.94%
controls:4.81%
cases:0.00%
controls:1.43%
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
6
45
95
890
0
14
108
964
—
—
—
0
11
108
965
—
Otolaryngology
4 [38004449]
1.1e-02
—
-1.0e+50
—
—
—
—
cases:11.88%
controls:11.76%
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
12
110
89
825
—
0
9
108
969
—
—
—
—
ranitidine bismuth citrate; oral
A02BA07 [21600088]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
hydrocortisone
C05AA01 [21601608]
1.8e-01
8.1e-01
-1.0e+50
—
—
-1.0e+50
1.4e-02
cases:11.88%
controls:10.16%
cases:5.56%
controls:2.56%
cases:0.00%
controls:0.51%
—
—
—
—
cases:0.00%
controls:2.25%
cases:7.55%
controls:7.45%
12
95
89
840
6
25
102
953
0
5
108
973
—
—
0
22
108
954
8
72
98
894
lenograstim; parenteral
L03AA10 [21603854]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
108
972
—
—
—
—
—
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
108
971
—
norethisterone; oral
G03DC02 [21602553]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
0
5
101
930
—
—
—
—
—
0
9
106
957
cefuroxime; oral, parenteral
J01DC02 [21602884]
4.2e-01
—
—
—
—
—
—
cases:4.95%
controls:3.32%
—
—
—
—
—
—
—
—
—
—
—
—
5
31
96
904
—
—
—
—
—
—
dexamethasone; oral, parenteral
H02AB02 [21602730]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
0
7
108
971
—
—
—
—
0
9
106
957
Internal Medicine
11 [38004456]
5.8e-01
—
-1.0e+50
—
-1.0e+50
—
-4.5e-01
cases:7.92%
controls:4.60%
—
—
cases:0.00%
controls:0.82%
—
—
cases:0.00%
controls:0.82%
—
—
cases:9.43%
controls:14.08%
8
43
93
892
—
0
8
108
970
—
0
8
108
970
—
10
136
96
830
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
9.7e-01
—
—
—
—
—
—
cases:4.95%
controls:1.93%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
96
917
—
—
—
—
—
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
—
9.5e-01
-1.0e+50
—
—
—
—
—
—
cases:4.63%
controls:1.84%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
5
18
103
960
0
5
108
973
—
—
—
—
False labour before 37 completed weeks of gestation
O47.0 [45582556]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
phenylephrine, combinations
R01BA53 [21603214]
2.8e-01
—
—
—
—
-1.0e+50
—
cases:6.93%
controls:5.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
7
50
94
885
—
—
—
—
0
13
108
963
—
Supervision of normal pregnancy, unspecified
Z34.9 [45566420]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
temazepam; oral
N05CD07 [21604642]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
3.2e-01
2.7e-01
—
—
1.3e+00
4.9e-01
-2.4e-01
cases:4.95%
controls:3.64%
cases:5.56%
controls:4.29%
—
—
—
—
cases:4.63%
controls:1.33%
cases:5.56%
controls:3.48%
cases:4.72%
controls:5.90%
5
34
96
901
6
42
102
936
—
—
5
13
103
965
6
34
102
942
5
57
101
909
Physical Medicine And Rehabilitation
25 [38004468]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
0
9
108
969
—
—
—
0
6
108
970
—
Assistance to normal delivery
MAX99 [2001306918]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
fluticasone; inhalant
R03BA05 [21603288]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:2.45%
cases:0.00%
controls:0.61%
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
0
24
108
954
0
6
108
972
—
0
5
108
973
—
—
valsartan; oral
C09CA03 [21601826]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Acute tonsillitis, unspecified
J03.9 [45576942]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
0
11
106
955
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Senile nuclear cataract
H25.1 [45581628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
dexamethasone and antiinfectives
S01CA01 [21603652]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
106
958
norethisterone and ethinylestradiol
G03AA05 [21602478]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
101
929
—
—
—
—
—
—
beclometasone; nasal
R01AD01 [21605043]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
hydrocortisone; oral, parenteral
H02AB09 [21602737]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.23%
—
—
—
—
—
—
—
—
—
—
—
0
12
108
966
—
—
—
—
—
dextromethorphan, combinations; oral
N07XX59 [43534835]
2.8e-01
—
—
—
—
-1.0e+50
—
cases:6.93%
controls:5.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
7
50
94
885
—
—
—
—
0
13
108
963
—
Leukocytes [Presence] in Urine
33052-2 [3045414]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
106
961
Thyroid insufficiency
104 [2001600104]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
7
106
959
insulin glargine; parenteral
A10AE04 [21600739]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
101
930
—
—
—
—
—
—
bisoprolol; oral
C07AB07 [21601689]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
Spontaneous vertex delivery
O80.0 [45577661]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
101
924
—
—
—
—
—
—
Carpal tunnel syndrome
G56.0 [45566891]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
6
106
960
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
108
973
—
—
—
—
—
Other specified special examinations
Z01.8 [45581003]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.23%
—
—
—
—
—
—
—
0
12
108
964
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
69
307
2.74
10.49
8.6
3.4
3.71
3.60
e6/l
0.03
46
146
109
611
2.41
10.15
5.7
2.3
—
—
—
0
0
43
157
3.11
9.29
7.3
13.2
105.79
104.99
mmol/l
0.62
43
157
106
614
2.28
8.88
12.5
3.4
10.42
48.40
e6/l
2.63
90
467
28
80
3.82
8.81
8.4
6.8
191.05
306.86
mg/l
0.48
22
51
36
122
3.29
8.78
4.4
4.9
60.68
65.84
e9/l
0.44
28
85
15
13
12.20
8.69
3.1
2.1
—
—
—
0
0
14
11
13.41
8.48
3.1
3.4
—
—
—
0
0
95
544
2.22
8.01
12.0
3.3
0.07
0.24
e6/l
2.47
76
401
140
946
2.12
7.59
7.8
3.1
6.37
6.32
ph
0.24
81
478
122
792
2.08
7.26
14.3
4.1
28.10
55.49
e6/l
1.42
92
507
27
89
3.29
6.86
6.3
3.4
—
—
—
0
0
30
106
3.09
6.81
7.1
2.7
0.21
0.23
e6/l
0.07
30
99
184
1419
2.19
6.60
11.5
4.3
—
—
—
0
0
51
246
2.36
6.31
19.2
10.4
7.37
7.37
ph
0.01
44
161
46
217
2.38
5.96
20.9
12.7
—
—
—
0
0
23
76
3.24
5.82
8.3
11.3
0.68
0.62
%
0.34
23
76
110
731
1.92
5.75
23.1
10.0
1.23
1.22
mmol/l
1.91
102
644
30
117
2.78
5.72
2.7
1.7
197.69
165.49
u/ml
0.20
13
66
68
391
2.02
5.36
10.4
3.2
7.38
7.39
ph
1.68
49
274
78
478
1.93
5.09
3.8
5.6
1.05
1.06
inr
0.04
66
405
141
1045
1.82
4.99
8.3
6.3
6.12
5.97
mmol/l
0.27
126
917
149
1124
1.83
4.96
9.0
3.4
0.00
0.00
estimate
-0.00
27
255
17
53
3.37
4.71
1.5
1.3
—
—
—
0
0
149
1135
1.80
4.69
9.2
3.5
0.15
0.00
estimate
0.49
27
244
149
1135
1.80
4.69
9.1
3.4
0.15
0.00
estimate
0.49
27
245
117
834
1.77
4.60
7.6
3.0
0.00
0.01
estimate
0.80
26
218
16
49
3.42
4.55
2.3
1.8
14.81
19.55
ng/l
1.23
16
49
24
94
2.72
4.54
4.0
1.5
125.00
108.66
au/ml
—
9
32
33
152
2.35
4.49
2.8
1.9
6.40
6.47
ph
0.19
24
101
7
6
11.96
4.30
5.7
3.5
1164.71
2477.50
mg
—
7
6
91
621
1.74
4.05
2.8
2.5
—
—
—
0
0
13
38
3.55
3.37
6.6
19.1
67.46
67.46
%
0.00
13
38
11
28
4.06
3.33
15.0
1.9
6.02
5.17
pmol/l
0.41
11
28
13
43
3.14
3.30
11.1
2.1
7.38
7.42
ph
1.92
13
43
163
1345
1.63
3.22
5.3
3.6
50.12
50.56
ug/l
0.03
158
1286
122
945
1.58
3.10
3.4
3.1
—
—
estimate
—
0
0
64
425
1.68
3.03
5.6
5.6
96.31
91.99
%
0.78
64
417
90
659
1.58
2.87
7.1
6.3
—
—
—
0
0
79
564
1.59
2.79
7.4
3.0
1.01
1.02
kg/l
2.86
57
346
11
35
3.24
2.68
13.8
2.3
—
—
—
0
0
51
332
1.68
2.58
4.1
4.2
—
—
—
0
0
5
7
7.26
2.56
1.6
2.1
147.80
87.69
mmol/24h
—
5
7
12
45
2.75
2.49
10.3
4.4
36.98
37.04
°c
0.41
12
45
29
162
1.90
2.44
2.5
1.8
0.00
0.00
estimate
—
6
48
10
33
3.11
2.38
1.9
1.8
—
—
—
0
0
10
33
3.11
2.38
1.9
1.8
—
—
—
0
0
10
33
3.11
2.38
1.9
1.8
—
—
—
0
0
10
33
3.11
2.38
1.9
1.8
—
—
—
0
0
32
189
1.80
2.27
28.0
7.6
4.90
5.09
kpa
1.71
32
178
35
213
1.75
2.25
1.8
2.3
—
—
—
0
0
5
9
5.64
2.22
1.8
1.4
1.22
1.19
mmol/l
—
5
9
5
9
5.64
2.22
1.8
1.4
4.00
3.72
mmol/l
—
5
9
5
9
5.64
2.22
1.8
1.4
105.80
106.33
mmol/l
—
5
9
26
145
1.89
2.21
32.9
8.0
10.43
9.77
kpa
1.84
26
137
35
215
1.73
2.18
33.1
15.9
24.35
25.20
mmol/l
1.56
35
215
13
55
2.44
2.16
2.5
2.7
110.62
116.16
ng/l
0.03
13
49
97
760
1.46
2.13
4.3
5.4
12.18
10.29
umol/l
0.51
85
704
9
32
2.88
2.02
10.1
2.5
10.90
9.74
kpa
—
9
32
9
32
2.88
2.02
14.7
2.5
4.74
4.87
kpa
—
9
32
16
79
2.10
1.90
1.9
1.5
—
—
—
0
0
16
79
2.10
1.90
1.2
1.1
—
—
—
0
0
39
261
1.59
1.78
2.6
1.5
—
—
—
0
0
84
662
1.41
1.72
6.9
2.6
0.00
0.00
estimate
0.50
25
216
78
611
1.41
1.65
7.9
3.3
0.00
0.00
estimate
0.50
26
243
25
152
1.72
1.64
31.1
8.1
—
—
—
0
0
5
14
3.62
1.62
1.2
1.0
—
—
—
0
0
5
14
3.62
1.62
1.2
1.1
—
—
—
0
0
221
2073
1.67
1.61
19.3
10.7
22.23
20.81
mg/l
0.29
191
1583
31
202
1.61
1.58
1.7
1.5
—
—
—
0
0
31
202
1.61
1.58
1.7
1.6
—
—
—
0
0
10
44
2.33
1.57
5.5
5.8
—
—
—
0
0
65
497
1.42
1.57
2.0
1.7
—
—
—
0
0
34
232
1.54
1.44
3.8
4.3
4.33
8.30
umol/l
1.18
27
179
106
891
1.33
1.41
2.2
1.9
—
—
—
0
0
7
29
2.45
1.40
9.9
23.3
10.47
11.96
%
—
7
29
141
1242
1.32
1.32
11.2
8.8
3.75
3.86
e9/l
0.29
125
1070
35
248
1.48
1.26
2.2
1.6
—
—
—
0
0
7
143
0.47
1.25
1.3
1.5
—
—
—
0
0
73
590
1.34
1.24
2.9
2.7
2.59
2.34
mg/l
0.62
67
517
11
56
2.01
1.24
2.0
2.0
—
—
—
0
0
6
26
2.34
1.19
9.5
2.5
—
—
—
0
0
34
244
1.46
1.16
1.2
1.3
109.67
115.75
u/ml
0.05
13
84
34
244
1.46
1.16
2.9
2.5
76.31
551.14
ng/l
1.94
16
95
87
732
1.29
1.10
10.4
8.0
—
—
—
0
0
49
385
1.34
1.00
1.6
1.4
19.02
19.25
nmol/l
0.05
43
348
118
1041
1.26
1.00
10.7
7.5
0.70
0.61
%
0.86
113
996
124
1103
1.25
0.97
10.7
7.4
0.04
0.04
e9/l
0.05
108
959
14
85
1.69
0.96
2.0
1.2
—
—
—
0
0
16
101
1.62
0.96
11.9
17.0
7.41
7.41
ph
—
8
50
124
1104
1.25
0.96
10.6
7.4
0.56
0.53
e9/l
0.60
108
961
118
1047
1.25
0.93
10.7
7.5
8.93
8.26
%
1.41
113
1001
8
43
1.89
0.88
12.4
14.3
—
—
—
0
0
6
30
2.02
0.87
1.2
5.0
—
—
—
0
0
117
1044
1.23
0.86
10.7
7.4
2.91
2.79
%
0.29
112
996
38
297
1.33
0.82
1.4
1.5
326.67
468.29
titre
—
6
41
17
114
1.53
0.82
1.5
1.4
—
—
—
0
0
6
34
1.78
0.77
2.3
1.2
305.00
294.38
mosm/kgh2o
—
6
24
126
1143
1.21
0.76
11.0
7.7
0.19
0.18
e9/l
0.26
116
1011
5
24
2.11
0.75
1.2
1.9
1.84
1.70
mmol/l
—
5
24
18
126
1.46
0.72
8.1
5.2
0.36
0.54
%
0.27
11
28
17
118
1.47
0.71
7.5
4.9
0.33
0.08
%
—
9
25
5
26
1.94
0.71
2.4
2.2
—
—
—
0
0
174
1636
1.22
0.70
4.3
3.0
2.60
2.67
mmol/l
0.58
168
1574
120
1092
1.19
0.68
9.7
7.1
52.03
53.76
%
0.92
115
1061
127
1164
1.19
0.66
10.6
7.2
2.07
2.11
e9/l
0.28
115
1046
26
201
1.33
0.62
8.6
3.1
—
—
—
0
0
5
30
1.68
0.62
19.6
19.8
1.44
1.09
mmol/l
—
5
24
0
22
0.00
0.59
0.0
1.2
—
—
—
0
0
124
1143
1.17
0.58
2.6
2.5
—
—
—
0
0
38
315
1.24
0.55
1.6
1.6
—
—
—
0
0
9
63
1.44
0.53
1.0
1.1
—
—
—
0
0
12
83
1.47
0.53
1.2
1.8
1.21
1.18
g/l
0.18
12
77
12
83
1.47
0.53
1.2
1.8
0.23
0.21
g/l
0.26
12
78
9
64
1.42
0.52
1.0
1.1
—
—
—
0
0
159
1506
1.16
0.49
3.9
2.7
1.12
1.10
mmol/l
0.17
154
1442
18
138
1.33
0.47
2.3
3.2
5.82
4.65
umol/l
0.27
13
104
46
398
1.19
0.45
2.1
2.9
0.70
0.75
mg/l
0.12
30
269
17
130
1.33
0.45
7.9
5.4
0.00
0.00
%
—
7
25
170
1623
1.15
0.45
4.2
2.9
1.42
1.43
mmol/l
0.23
164
1559
19
240
0.77
0.45
1.2
1.4
3.56
3.21
mmol/l
0.68
14
151
5
31
1.63
0.43
1.2
1.1
—
—
—
0
0
5
33
1.53
0.41
1.4
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
1.80
—
0
15
60
536
1.16
0.41
10.0
3.8
—
—
—
0
0
8
60
1.34
0.40
1.3
1.2
—
—
—
0
0
16
124
1.31
0.40
8.7
5.2
0.00
0.00
%
—
9
25
0
19
0.00
0.39
0.0
1.9
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
14.51
—
0
19
13
98
1.34
0.38
6.8
1.7
—
—
—
0
0
5
76
0.65
0.36
1.0
1.7
—
—
—
0
0
37
322
1.18
0.35
2.4
2.0
—
—
—
0
0
12
155
0.76
0.34
2.2
1.9
8.25
9.16
nmol/l
0.15
12
143
28
326
0.84
0.33
1.4
1.2
1.85
4.37
u/ml
1.06
11
124
186
1915
0.88
0.33
5.4
5.0
1.88
1.80
mu/l
0.44
180
1833
170
1639
1.12
0.33
4.3
3.0
4.34
4.46
mmol/l
1.15
165
1579
21
174
1.23
0.32
1.2
1.3
—
—
—
0
0
36
315
1.17
0.32
1.4
1.2
—
—
—
0
0
7
98
0.71
0.31
2.4
1.7
—
7.16
—
0
24
15
120
1.27
0.31
1.3
1.2
—
26.73
—
0
6
95
891
1.11
0.30
2.0
2.0
—
—
—
0
0
44
394
1.14
0.30
1.9
2.5
13938.00
4229.48
u/l
0.97
17
158
13
162
0.79
0.29
1.1
1.1
—
—
—
0
0
71
658
1.11
0.28
1.8
1.8
—
—
—
0
0
72
773
0.90
0.27
1.8
1.6
1.52
1.88
g/l
1.55
47
461
11
86
1.29
0.26
1.4
2.2
1.76
5.57
iu/l
—
5
37
51
467
1.12
0.25
2.5
3.1
40.61
94.54
ug/g
5.19
42
361
165
1695
0.92
0.22
4.6
4.3
14.55
14.35
pmol/l
0.52
156
1548
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
48
1.26
0.20
1.2
1.6
5.48
6.90
mmol/l
—
6
48
219
2159
1.14
0.20
14.8
8.6
—
—
—
0
0
38
414
0.90
0.19
1.6
1.9
—
—
—
0
0
35
383
0.90
0.19
1.6
2.0
—
—
—
0
0
12
100
1.21
0.18
1.2
1.6
—
—
—
0
0
41
379
1.10
0.17
1.9
2.2
11.46
14.44
ng/l
0.42
16
123
7
62
1.13
0.17
12.6
18.0
0.74
0.63
%
—
7
62
38
411
0.91
0.17
1.6
1.9
—
—
—
0
0
38
411
0.91
0.17
1.6
1.9
—
—
—
0
0
38
411
0.91
0.17
1.6
1.9
—
—
—
0
0
31
339
0.90
0.17
1.3
1.2
15.67
14.56
iu/ml
—
6
69
83
867
0.94
0.16
1.5
1.6
1.42
2.37
u/ml
0.42
14
212
8
71
1.13
0.16
1.1
1.1
—
—
—
0
0
16
182
0.87
0.15
1.7
2.4
—
—
—
0
0
63
600
1.07
0.14
1.7
1.6
92.32
94.68
pmol/l
0.17
36
325
5
45
1.11
0.10
10.0
3.9
1.96
3.39
e9/l
—
5
45
23
213
1.09
0.09
1.3
1.4
172.16
269.36
miu/ml
0.70
13
116
23
213
1.09
0.09
1.2
1.3
—
—
—
0
0
5
46
1.09
0.09
1.0
1.1
—
—
—
0
0
5
47
1.07
0.09
1.0
1.1
—
—
—
0
0
20
184
1.09
0.09
1.1
1.2
—
—
—
0
0
6
58
1.04
0.08
1.0
1.1
—
—
—
0
0
7
65
1.08
0.08
12.6
17.3
0.87
1.22
%
—
7
65
7
65
1.08
0.08
12.6
17.4
97.27
94.76
%
—
7
65
19
176
1.09
0.07
1.5
1.9
8.39
9.72
iu/l
0.19
13
135
9
88
1.02
0.07
1.0
1.0
1.46
1.53
g/l
—
9
88
9
88
1.02
0.07
1.0
1.0
0.84
0.79
g/l
—
9
88
164
1624
1.03
0.05
3.9
2.7
5.46
5.37
mmol/l
0.38
156
1497
30
289
1.04
0.04
1.7
2.2
—
—
—
0
0
62
608
1.03
0.03
1.5
1.7
—
—
—
0
0
73
718
1.02
0.03
2.3
1.9
—
—
—
0
0
15
157
0.95
0.01
1.1
1.2
0.62
4.11
u/ml
—
9
106
137
1362
1.01
0.01
3.3
3.3
27.57
27.70
u/l
0.01
130
1314
13
124
1.05
0.00
1.0
1.2
—
—
—
0
0
19
188
1.01
0.00
1.6
1.7
—
—
—
0
0
94
937
1.01
0.00
2.0
1.9
—
—
—
0
0
105
1047
1.01
0.00
12.8
9.5
0.00
0.00
e9/l
0.27
85
838
14
136
1.03
0.00
1.2
1.0
—
—
—
0
0
19
194
0.98
0.00
1.6
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.0
—
32.00
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
361.17
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
37.1
—
0.55
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
5
55
0.91
-0.00
1.0
3.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
6.16
—
0
5
5
51
0.98
-0.00
2.6
2.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
6
66
0.91
-0.00
10.8
3.1
41.45
54.16
%
—
6
66
0
7
0.00
-0.00
0.0
8.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
66.76
—
0
5
6
68
0.88
-0.00
1.2
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
9.11
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: Q17_CONGENITAL_VESICOURETERAL_REFLUX – Congenital vesicoureteral reflux

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).